| Mary Pell Abernathy, MD | |
|
1429 N 6th St, Terre Haute, IN 47807-1019 | |
| (812) 242-3115 | |
| Not Available |
| Full Name | Mary Pell Abernathy |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 34 Years |
| Location | 1429 N 6th St, Terre Haute, Indiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073559027 | NPI | - | NPPES |
| 100378350 | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207VM0101X | Obstetrics & Gynecology - Maternal & Fetal Medicine | 01042086 (Indiana) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Union Associated Physicians Clinic Llc | 3375687437 | 159 |
News Archive
The benefits of race-conscious college admissions are only fully realized under certain conditions, concludes new University of Maryland-led research. To stimulate meaningful cross-racial engagement, incoming freshman classes should reflect both racial and socio-economic diversity, the researchers report.
Antares Pharma, Inc. today announced the approval of OTREXUP (methotrexate) injection by the U.S. Food and Drug Administration. OTREXUP is the first FDA approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.
Immigrants to the U.S. contributed $115.2 billion more to Medicare's Hospital Trust Fund during the past decade than they withdrew, casting doubt on criticism they overburden the health plan for the elderly and disabled, according to a study by researchers from Harvard and the City University of New York.
Cohera Medical, Inc., a rapidly growing medical device company, announced today that it has received CE Mark approval for its lead product, TissuGlu® Surgical Adhesive. CE Mark approval allows TissuGlu to be sold in the European Union.
The U.S. Food and Drug Administration today expanded the approved use of Exjade (deferasirox) to treat patients ages 10 years and older who have chronic iron overload resulting from a genetic blood disorder called non-transfusion-dependent thalassemia (NTDT).
› Verified 6 days ago
| Entity Name | Union Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013965573 PECOS PAC ID: 8426943614 Enrollment ID: O20040519000807 |
News Archive
The benefits of race-conscious college admissions are only fully realized under certain conditions, concludes new University of Maryland-led research. To stimulate meaningful cross-racial engagement, incoming freshman classes should reflect both racial and socio-economic diversity, the researchers report.
Antares Pharma, Inc. today announced the approval of OTREXUP (methotrexate) injection by the U.S. Food and Drug Administration. OTREXUP is the first FDA approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.
Immigrants to the U.S. contributed $115.2 billion more to Medicare's Hospital Trust Fund during the past decade than they withdrew, casting doubt on criticism they overburden the health plan for the elderly and disabled, according to a study by researchers from Harvard and the City University of New York.
Cohera Medical, Inc., a rapidly growing medical device company, announced today that it has received CE Mark approval for its lead product, TissuGlu® Surgical Adhesive. CE Mark approval allows TissuGlu to be sold in the European Union.
The U.S. Food and Drug Administration today expanded the approved use of Exjade (deferasirox) to treat patients ages 10 years and older who have chronic iron overload resulting from a genetic blood disorder called non-transfusion-dependent thalassemia (NTDT).
› Verified 6 days ago
| Entity Name | University Obstetricians-gynecologists,inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235177924 PECOS PAC ID: 5092796466 Enrollment ID: O20040601000544 |
News Archive
The benefits of race-conscious college admissions are only fully realized under certain conditions, concludes new University of Maryland-led research. To stimulate meaningful cross-racial engagement, incoming freshman classes should reflect both racial and socio-economic diversity, the researchers report.
Antares Pharma, Inc. today announced the approval of OTREXUP (methotrexate) injection by the U.S. Food and Drug Administration. OTREXUP is the first FDA approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.
Immigrants to the U.S. contributed $115.2 billion more to Medicare's Hospital Trust Fund during the past decade than they withdrew, casting doubt on criticism they overburden the health plan for the elderly and disabled, according to a study by researchers from Harvard and the City University of New York.
Cohera Medical, Inc., a rapidly growing medical device company, announced today that it has received CE Mark approval for its lead product, TissuGlu® Surgical Adhesive. CE Mark approval allows TissuGlu to be sold in the European Union.
The U.S. Food and Drug Administration today expanded the approved use of Exjade (deferasirox) to treat patients ages 10 years and older who have chronic iron overload resulting from a genetic blood disorder called non-transfusion-dependent thalassemia (NTDT).
› Verified 6 days ago
| Entity Name | Union Associated Physicians Clinic Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891028379 PECOS PAC ID: 3375687437 Enrollment ID: O20100213000002 |
News Archive
The benefits of race-conscious college admissions are only fully realized under certain conditions, concludes new University of Maryland-led research. To stimulate meaningful cross-racial engagement, incoming freshman classes should reflect both racial and socio-economic diversity, the researchers report.
Antares Pharma, Inc. today announced the approval of OTREXUP (methotrexate) injection by the U.S. Food and Drug Administration. OTREXUP is the first FDA approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.
Immigrants to the U.S. contributed $115.2 billion more to Medicare's Hospital Trust Fund during the past decade than they withdrew, casting doubt on criticism they overburden the health plan for the elderly and disabled, according to a study by researchers from Harvard and the City University of New York.
Cohera Medical, Inc., a rapidly growing medical device company, announced today that it has received CE Mark approval for its lead product, TissuGlu® Surgical Adhesive. CE Mark approval allows TissuGlu to be sold in the European Union.
The U.S. Food and Drug Administration today expanded the approved use of Exjade (deferasirox) to treat patients ages 10 years and older who have chronic iron overload resulting from a genetic blood disorder called non-transfusion-dependent thalassemia (NTDT).
› Verified 6 days ago
| Entity Name | Community Physicians Of Indiana Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619105244 PECOS PAC ID: 1759416662 Enrollment ID: O20100317000717 |
News Archive
The benefits of race-conscious college admissions are only fully realized under certain conditions, concludes new University of Maryland-led research. To stimulate meaningful cross-racial engagement, incoming freshman classes should reflect both racial and socio-economic diversity, the researchers report.
Antares Pharma, Inc. today announced the approval of OTREXUP (methotrexate) injection by the U.S. Food and Drug Administration. OTREXUP is the first FDA approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.
Immigrants to the U.S. contributed $115.2 billion more to Medicare's Hospital Trust Fund during the past decade than they withdrew, casting doubt on criticism they overburden the health plan for the elderly and disabled, according to a study by researchers from Harvard and the City University of New York.
Cohera Medical, Inc., a rapidly growing medical device company, announced today that it has received CE Mark approval for its lead product, TissuGlu® Surgical Adhesive. CE Mark approval allows TissuGlu to be sold in the European Union.
The U.S. Food and Drug Administration today expanded the approved use of Exjade (deferasirox) to treat patients ages 10 years and older who have chronic iron overload resulting from a genetic blood disorder called non-transfusion-dependent thalassemia (NTDT).
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mary Pell Abernathy, MD 6626 E 75th St Ste 500, Indianapolis, IN 46250-2890 Ph: () - | Mary Pell Abernathy, MD 1429 N 6th St, Terre Haute, IN 47807-1019 Ph: (812) 242-3115 |
News Archive
The benefits of race-conscious college admissions are only fully realized under certain conditions, concludes new University of Maryland-led research. To stimulate meaningful cross-racial engagement, incoming freshman classes should reflect both racial and socio-economic diversity, the researchers report.
Antares Pharma, Inc. today announced the approval of OTREXUP (methotrexate) injection by the U.S. Food and Drug Administration. OTREXUP is the first FDA approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.
Immigrants to the U.S. contributed $115.2 billion more to Medicare's Hospital Trust Fund during the past decade than they withdrew, casting doubt on criticism they overburden the health plan for the elderly and disabled, according to a study by researchers from Harvard and the City University of New York.
Cohera Medical, Inc., a rapidly growing medical device company, announced today that it has received CE Mark approval for its lead product, TissuGlu® Surgical Adhesive. CE Mark approval allows TissuGlu to be sold in the European Union.
The U.S. Food and Drug Administration today expanded the approved use of Exjade (deferasirox) to treat patients ages 10 years and older who have chronic iron overload resulting from a genetic blood disorder called non-transfusion-dependent thalassemia (NTDT).
› Verified 6 days ago
Charles Sides, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1429 N 6th St, Terre Haute, IN 47807 Phone: 812-242-3115 | |
Grant Harold Hammons Iii, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1429 N 6th St, Terre Haute, IN 47807 Phone: 812-232-0564 Fax: 812-242-4518 | |
Isaac N Mitre, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1623 N 4th Street, Terre Haute, IN 47804 Phone: 812-238-1652 Fax: 812-238-2648 | |
Robert C Lalouche, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1429 N 6th St, Terre Haute, IN 47807 Phone: 812-242-3115 Fax: 812-235-9580 | |
Dr. Ramon R Contreras, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 3464 S 4th St, Terre Haute, IN 47802 Phone: 812-234-8117 Fax: 812-234-1894 | |
Victoria L Potoczak, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3618 S 4th St, Terre Haute, IN 47802 Phone: 812-238-8887 Fax: 812-238-9166 |